Связанная с Ocrelizumab организация пневмонии в множестве склерозов: выводы из серии дел и обзор литературы.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Petza Enrico, Guerrieri Simone, Marino Veronica, Gattuso Irene, Rubin Martina, Nozzolillo Agostino, Rocca Maria A, Moiola Lucia, Filippi Massimo
Аннотация
Оригинал публикации
Ocrelizumab-related organizing pneumonia in multiple sclerosis: insights from a case series and literature review.
BACKGROUND: Organizing pneumonia (OP) is a rare interstitial lung disease that may occur secondary to drug exposure. Although OP has been described during rituximab treatment, the association with ocrelizumab remains elusive, with evidence limited to a few recent cases. We aimed to characterize ocrelizumab-related OP in the context of the existing literature.
METHODS: Clinical, radiological, laboratory, therapeutic, and outcome data were retrospectively collected from multiple sclerosis (MS) patients with ocrelizumab-associated OP at our center and descriptively compared with 17 cases identified through a literature review.
RESULTS: Among 626 ocrelizumab-treated MS patients, five cases of OP were observed (0.8%) (3 females, median age=54 years, range=27-64). OP developed after a mean treatment exposure of 5.1 years (standard deviation (SD=2.9) and a mean interval of 10.8 weeks (SD=10.4) following the last infusion. Clinical presentation was characterized by persistent antibiotic-refractory fever, sometimes accompanied by nonproductive cough. Chest CT consistently showed patchy ground-glass opacities and consolidations. All patients received prednisone 0.5-1 mg/kg/day for a median duration of 30 days (range=15-60), followed by gradual tapering. Despite initial clinical response, respiratory relapses and residual radiological lung abnormalities were observed in four patients during a median follow-up of 29 months (range=4-47). Ocrelizumab was discontinued in all patients. Only one patient initiated ozanimod two years after OP onset.
DISCUSSION: Our findings support the emerging evidence of ocrelizumab-related OP and show substantial consistency with previously reported cases. Further studies are needed to clarify the potential role of CD20+ lymphocyte depletion in OP pathogenesis.